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Chronic kidney disease has the potential to induce sequelae that
can have severe and mortal outcomes. In particular, impaired
glomerular filtration can cause a hyperphosphatemic state,
which, if left unchecked, can lead to secondary hyperparathy-
roidism, vascular calcification, and renal osteodystrophy. Thera-
peutic management of hyperphosphatemia must maintain both
phosphorus and calcium serum concentrations within the rec-
ommended guidelines. The balance of both minerals is regulated
by parathyroid hormone; thus, an imbalance of one affects the
other. In end-stage renal disease, patients often present with
hypocalcemic levels due to the kidneys’ inability to generate ac-
tive vitamin D to promote calcium absorption in the intestine.
Absorption of calcium can be increased by the administration
of active vitamin D analogues. Minimizing phosphorus intake
through a strict dietary regimen, combined with the use of phos-
phate binders to absorb excess ingested phosphate, can help to
maintain serum phosphate levels near the recommended con-
centration of 5.5 mg/dL. Phosphate-binding compounds have
evolved from the original aluminum-based binders pioneered
in the 1970s to calcium-based binders such as calcium acetate,
and more recently, to the following additions to the nephrol-
ogist’s armamentarium: sevelamer—a polyhydrochloride poly-
mer, and lanthanum carbonate. One of the top 2 common clin-
ical treatments for hyperphosphatemia, calcium acetate, has an
established history of efficacy since the 1980s, and has been
shown to be cost effective and well tolerated, as well.
Overall, it is estimated that there are more than 19
million adult Americans affected by chronic kidney dis-
ease [1]. The most advanced stage, called end-stage renal
disease (ESRD), which is classified as stage 5 by the Na-
tional Kidney Foundation [2] affects more than 500,000
people in the United States, according to the National
Institutes of Health 2002 prevalence report [3]. Approxi-
mately $15 billion in Medicare expenses are incurred an-
nually by ESRD patients [3], who suffer from bone and
cardiovascular complications due to progressive renal in-
sufficiency. An inefficient glomerular filtration rate ele-
vates serum phosphate levels, promoting consequences
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such as secondary hyperparathyroidism, vascular calcifi-
cation, and renal osteodystrophy. A survey of more than
6000 hemodialysis patients estimates that the national
mean serum phosphate level is 6.2 mg/dL, well above
the recommended 5.5 mg/dL maximum [4] (Table 1) [5].
Hyperphosphatemia is a problem in approximately 60%
of U.S. hemodialysis patients, indicating a need for im-
proved therapeutic management [4]. Another metabolic
problem related to ESRD is hypocalcemia caused by the
diseased kidney’s inability to generate enough active vita-
min D for intestinal calcium absorption. As a direct result,
an excess of parathyroid hormone (PTH) is secreted, a
condition termed secondary hyperparathyroidism [6, 7].
High levels of PTH induce an elevated release of calcium
from bone, increasing metabolic calcium concentrations.
The most common associated parathyroid abnor-
mality in secondary hyperparathyroidism is quadra-
glandular hyperplasia—the overgrowth of the 4 parathy-
roid glands—resulting in PTH oversecretion [7]. In
healthy individuals, PTH regulates the body’s phosphorus
and calcium balance by inducing calcium and phosphorus
release from bone, and by stimulating the kidneys to re-
absorb or excrete the minerals as necessary [8]. PTH also
induces the renal enzyme 1-a-hydroxylase to produce ac-
tive vitamin D to facilitate the intestinal absorption of
calcium [8]. Secretion of PTH is negatively regulated by
active vitamin D, ensuring against the overproduction of
the hormone [8]. PTH induces multinuclear giant cells
(osteoclasts) to dissolve and release calcium from bony
spicules, thus remedying a hypocalcemic state. In patients
who lack optimal dialysis and, thus, have a metabolic im-
balance, the consequence is arthropathy in the form of
calcium, phosphate, and pyrophosphate deposits around
interphalangeal joints, the shoulders, and the hips. In ad-
dition, there is dissolution of the phalanges from the os-
teoplastic cavity, a condition that becomes more severe
until the secondary hyperparathyroidism is corrected. Se-
vere bone disease can cause rheumatologic and/or ortho-
pedic problems, and interfere with hematopoiesis, if bone
marrow fibrosis develops [9]. Potentially, one of the more
severe consequences of unchecked hyperparathyroidism
is pathologic fracture due to bone dissolution.
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Table 1. Recommended target mineral and hormone concentrations
for ESRD patients [5]
Serum calcium 9.2–9.6 mg/dL (2.3–2.4 mmol/L)
Serum phosphorus 2.5–5.5 mg/dL (0.81–1.78 mmol/L)
Calcium-phosphorus product <55 mg2/dL2 (<4.46 mmol2/L2)
Intact parathyroid hormone 100–200 pg/mL
Excess PTH is also correlatively linked to intractable
pruritus, which is likely due to cutaneous calcification,
if analogous to the mechanism of uremia-induced pru-
ritus. Similarly, it has been proposed by Jeffrey Burline,
Editor of Nephron, that high PTH concentrations can
result in calcium pyrophosphate being deposited in the
conjunctiva of the eye, analogous to mineral deposits in
the joints. This may be the antecedent of the red eyes of
uremic patients. An elevated calcium-phosphate prod-
uct readily develops in hemodialysis patients who tend to
have a net-positive calcium imbalance (Table 1). Calcium
absorption from dialysate combined with abnormal bone
turnover and buffering contributes to the calcium burden
[4]. Elevated calcium-phosphate product and phosphate
concentrations are significant predictors of cardiovascu-
lar mortality in ESRD patients [4, 10]. Cardiovascular dis-
ease is implicated in almost half of dialysis patient deaths,
and cardiovascular calcification (also called arterial stiff-
ness or worsening atherosclerosis) can generate lesions
that frequently affect the myocardium, coronary arter-
ies, and cardiac valves [10]. Cardiovascular complications
include myocardial ischemia, myocardial infarction, im-
paired myocardial function, congestive heart failure, car-
diac valve insufficiency, and cardiac arrhythmias, leading
to substantial morbidity and mortality in ESRD patients
[10].
Chronic kidney failure is managed in part by limit-
ing phosphorous intake in the diet, using hemodialysis
or peritoneal dialysis and, for more than 15,000 patients
with ESRD, by undergoing kidney transplantation [3].
After a kidney transplant, quadra-glandular hyperplasia
may persist, creating an excess of PTH despite the nor-
malized calcium and phosphorus levels. The persistent
secretion of excess PTH from glands that could previ-
ously react to uremia has been labeled with the term au-
tonomous or tertiary hyperparathyroidism and can lead
to mortality. The cause of increased mortality in patients
with chronic renal failure and patients on dialysis with hy-
perparathyroidism has not been directly linked to either
phosphate retention or low calcium levels, and is a cur-
rent topic of controversy [7]. However, it is not contended
that the pathogenesis of hyperparathyroidism begins with
phosphate retention, is associated with decreased 1-a-
hydroxylation of 25-hydroxyl-D3 to form calcitriol, and
results in a hypocalcemic state.
Phosphorous is abundant in most foods, and North
American women typically ingest 1000 mg/day, while men
Table 2. Identifying risk factors for “poorly controlled” serum
phosphorus [12]
Diabetes
Active smoking
Female sex
White race
High serum creatinine levels
Poor compliance with dialysis regimen
Table 3. Methods for controlling hyperphosphatemia [13–16]
Restrict dietary phosphorous intake
Dialysis
Minimize phosphate absorption by the intestine (phosphate binders)
Increase active vitamin D to facilitate calcium absorption (calcitriol)
Diminish parathyroid hormone secretion without increasing
intestinal calcium absorption (vitamin D analogues:
22-oxacalcitriol, paricalcitol, doxercalciferol, alfacalcidol)
Increase the sensitivity of the calcium-sensing receptor of the
parathyroid gland to decrease parathyroid hormone secretion
(calcimimetics: R-56 and cinacalcet HCl)
ingest 1500 mg/day [11]. Approximately 60% to 70% of
ingested phosphorous is absorbed in the small bowel,
which the kidney filters and excretes 10% of the filtered
load [11]. Chronic kidney dysfunction hinders phospho-
rous removal and fosters a positive balance of phospho-
rus, often resulting in hyperphosphatemia [11] (Tables 2
[12] and 3 [13–16]). In the 1970s, reducing phosphate lev-
els with phosphate binders, such as aluminum hydroxide
and aluminum carbonate, was pioneered [1]. Insoluble
phosphate complexes are formed, which are excreted in
feces. Although the method was very effective at mini-
mizing ingested phosphate absorption, excess aluminum
was found to cause dialysis dementia, severe bone disease
(osteomalacia), muscle weakness, and anemia in some pa-
tients [17, 18].
Later, calcium was developed as an alternative phos-
phate binder, administered in various forms, including
calcium carbonate and calcium acetate commonly, as
well as calcium citrate, ketovalin, and alginate. Calcium
compounds do not bind phosphorus as effectively as
aluminum because of the pH dependence of the reaction.
Calcium salt dissociation is ameliorated by the low pH
of the stomach, but phosphorous binding requires a pH
greater than 5 [11]. However, calcium acetate became an
effective alternative to its antecedent, calcium carbonate,
because the acetate salt is 10,000 times more soluble in
water than the carbonate compound [11]. The quantity of
calcium acetate required to minimize dietary phosphorus
intake is much smaller than the amount of calcium car-
bonate because the acetate salt is able to absorb 6.8 mg
phosphorus/mEq calcium-absorbed compared with
2.5 mg phosphorus/mEq calcium-absorbed for the
carbonate compound [11]. Besides the benefit of ease
of usage for patients that likely results in better patient
compliance with the treatment regimen, this may be
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important for prolonged usage, as it has been suggested
that chronic excess calcium concentrations can lead to
metastatic calcification, including cardiac and coronary
artery calcification [7, 10].
The use of vitamin D treatments to foster calcium
absorption, combined with calcium-based phosphate
binders, adds another level of complexity to managing
secondary hyperparathyroidism for nephrologists. It has
been suggested that this combined therapy promotes my-
ocardial calcification and coronary artery calcification,
and results in a higher mortality rate. This is a valid
concern, as cardiovascular disease has been cited as the
cause of death in more than 45% of all dialysis patients
[19]. A report published by Block et al that included 2
large, random samples of hemodialysis patients did not
corroborate a connection between calcium levels and
mortality [12]. Data from the United States Renal Data
System (USRDS), collected in the Case Mix Adequacy
Special Study (1990) and the USDRS Dialysis Morbidity
and Mortality Study Wave 1 (1993), were systematically
analyzed to assess whether high serum calcium levels cor-
related with increased mortality in ESRD hemodialysis
patients who had received dialysis for a minimum of 1
year [12]. Logistic regression analysis conducted in this
independent study found that a high level of phosphorous
(>6.5 mg/dL) was linked to an increased mortality rate
(by 27%), while calcium levels were uncorrelated [12].
Similarly, PTH concentrations were independent of risk
of death. Comorbidity was found with abnormally high
calcium-phosphorous product, but the authors suggest
that the increased risk is driven by hyperphosphatemia
[12].
Braun et al used electron-beam computed tomogra-
phy (EBCT) to consider the number of calcifications, the
surface area, and the average and highest densities of
calcifications to compile a coronary artery calcium score
for 49 chronic hemodialysis patients and 102 nondialysis
patients. A stepwise, multiple regression analysis linked
hypertension and older age to higher coronary artery
calcium scores, while calcium and parathyroid hormone
scores were uncorrelated [20]. This suggests that there
is no link between the amount of calcium in the diet
and mortality and the development of coronary artery
calcification.
Coladonato et al have noted that many analyses that
correlate dietary intake of calcium to vascular calcifica-
tion fail to measure calcium intake and, instead, rely on
reported or prescribed calcium. These numbers are of-
ten highly skewed by the lack of treatment compliance,
which is a problem with approximately 65% to 80% of
dialysis patients who are prescribed calcium-based phos-
phate binders [18]. Other studies have suggested that
bone turnover rate may have a more significant effect
on the development of hypocalcemia than oral calcium
intake [11, 18, 21, 22].
Also, vascular calcification associated with chronic
kidney disease is not a new phenomenon. Well before
calcium-based phosphate binders began to be adminis-
tered for controlling hyperphosphatemia, studies showed
that extensive and often severe extraosseous soft tissue
calcification was prevalently correlated with patients un-
dergoing chronic dialysis. In a study conducted by Kuzela
et al, 79% of dialysis patients had soft tissue calcifi-
cation involving more than 1 internal viscus, most fre-
quently involving the heart, lungs, stomach, and kidneys,
compared with 44% of nondialysis patients (P value <
0.025) [23]. The study was unable to draw correlations
between serum calcium, serum phosphate, and calcium-
phosphorous product levels with the severity of soft tissue
calcification [23].
Hyperparathyroidism can best be managed by restor-
ing active vitamin D, normalizing serum calcium, and re-
ducing hyperphosphatemia (Table 3). The reduction of
serum phosphate concentrations can be accomplished
by administration of phosphate binders ranging from
aluminum-based binders, such as aluminum hydroxide
and aluminum carbonate, to calcium-based compounds,
including calcium acetate and calcium carbonate. Experi-
mentally, magnesium hydroxide and magnesium carbon-
ate were used for controlling phosphate levels, with mixed
results. Side effects such as diarrhea, hyperkalemia, and
hypermagnesemia were common. Neither agent has been
approved by the U.S. Food and Drug Administration [17].
The newest additions to the nephrologist’s armamen-
tarium are the calcium- and aluminum-free compounds,
including sevelamer—a poly hydrochloride polymer—
and lanthanum carbonate. It is unclear which phosphate
binder is the most effective while minimizing potentially
harmful side effects. The toxic effects of long-term ex-
cess aluminum consumption are well documented, but
the potential effects of increasing oral calcium intake are
controversial [10, 18]. Sevelamer is reported to provide
equivalent control of serum phosphorus as calcium-based
phosphate binders, with fewer potential side effects [24].
A study conducted by Chertow et al indicated that seve-
lamer may attenuate coronary and aortic calcification,
and likely does not induce hypercalcemia [24]. The study
found that patients who had rapid progression of calci-
fication also had higher mean serum calcium concentra-
tions, rates of hypocalcemia, and at least 1 hypocalcemic
episode [24]. However, multivariate analysis was not con-
ducted to draw a direct relationship between hypocal-
cemia, hypocalcemic episodes, and the progression of
calcification [25]. Furthermore, Fournier et al have sug-
gested that the mild hyperparathyroidism seen in the
study may have been corrected more simply by increas-
ing the dose of calcium carbonate without administer-
ing aluminum hydroxide or calcitriol [26]. Serum phos-
phate concentrations can be effectively managed with
higher doses of calcium carbonate, without a concomitant
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increase in serum calcium levels [26, 27]. Additionally,
the sevelamer study combined results from 2 groups of
patients that received calcium carbonate or calcium ac-
etate [28]. These calcium compounds are not equivalent
because calcium acetate has superior phosphate-binding
capacity, with half the amount of elemental calcium ab-
sorbed [28, 29]. Finally, the sevelamer study design did
not control for variables that could affect the rate of car-
diovascular calcification, including dialysate calcium, vi-
tamin D dose, and lipid levels, disallowing the conclusion
of a causal relationship between cardiovascular calcifi-
cation and possible calcium loading from calcium-based
binders [30].
Other alternative phosphate binders include the rare
earth metal, lanthanum, which is currently in clinical tri-
als for control of hyperphosphatemia. Lanthanum cations
are efficient phosphate binders, and are not absorbed well
by the gastrointestinal tract [17]. However, lanthanum
chloride can accumulate in tissues with extended in-
take and is toxic in the long term [17]. A short-term,
single-blind, placebo-controlled study of 196 hemodial-
ysis patients indicated that lanthanum carbonate may be
a safe, effective alternative as a phosphate binder [31]. A
randomized, double-blind, placebo-controlled phase III
study of lanthanum carbonate reported a change in serum
phosphorus concentrations from 6.25 (± 1.74) prestudy
to 5.94 (± 1.65) at week 11, the end of the study. The
placebo group phosphorus concentrations ranged from
6.19 (± 1.78) prestudy to 7.85 (± 1.96) at the end of the
study [32]. Lanthanum carbonate-treated patients had in-
creased incidence of nausea and vomiting over placebo;
otherwise, the safety and tolerability profiles for the treat-
ment and control groups were similar [31, 32]. While there
are lanthanum deposits in bone with chronic usage, pre-
liminary data indicate a localization that does not affect
the process of mineralization or the osteoblast number
and function [33].
There still remain several significant benefits to using
calcium acetate for controlling hyperphosphatemia. Fac-
tors such as high efficacy of phosphate control, decreased
toxicity, and lower annual cost are the most compelling
[34]. An 8-week, randomized, double-blind study of 100
hemodialysis patients called the Calcium Acetate Re-
nagel Evaluation, or CARE, study compared the effi-
cacy and toxicity of calcium acetate with sevelamer for
serum phosphate control [35]. The study found serum
phosphorus time-averaged concentration levels to be 1.08
mg/dL (P value = 0.0006) lower for calcium acetate-
treated patients and the calcium phosphorous product to
be 6.1 mg2/dL2 (P value = 0.022) lower, as well [35]. The
calcium acetate recipients attained a serum phosphorus
concentration at or below the recommended maximum
of 5.5 mg/dL within 3 weeks of treatment, whereas the
sevelamer-treated group did not reach the target level
within the 8- week study, despite steady dose escalation
Table 4. Thirty-day starting dose cost of phosphate binders (author’s
personal inquiry to local pharmacies—2003)
Calcium carbonate $8.06
Aluminum hydroxide $19.57
Calcium acetate $26.75
Sevelamer $108.98
[35]. Transient hypocalcemia occurred in 16.7% of the cal-
cium acetate recipients, all of whom were concomitantly
treated with intravenous vitamin D [35]. Qunibi et al rec-
ommend that judicious usage of vitamin D treatments
for patients taking calcium acetate may minimize the in-
cidences of hypercalcemia [35]. At least 1 hypocalcemic
episode has been observed in 50% of sevelamer-treated
patients compared with 27% of calcium acetate-treated
patients [35]. Chertow et al suggest that a nighttime sup-
plemental calcium dose of 900 mg daily may enhance
control of hyperparathyroidism [22, 36]. Week 8 intact
PTH levels were comparable between the calcium ac-
etate and sevelamer treatment groups, and overall, both
treatments were well tolerated with similar gastrointesti-
nal side effect profiles [35]. The CARE study did cor-
roborate previous findings that treatment with sevelamer
induces lower serum bicarbonate levels, potentially caus-
ing metabolic acidosis. Short-term metabolic acidosis can
stimulate bone dissolution and resorption, while long-
term acidosis can cause metabolic net-negative nitrogen
and protein imbalances [35, 37]. Calcium acetate also has
the benefit of being a fourth of the cost of sevelamer
(Table 4) [38]; in 2003, calcium acetate had a yearly cost
of ∼$780 compared with the mean pharmacy price of
∼$3300 for treatment with sevelamer [38].
CONCLUSION
Currently, sevelamer hydrochloride and calcium ac-
etate are the 2 most common clinical treatments for mini-
mizing phosphate intake [22]. Ongoing research may help
define the optimal treatment program for the manage-
ment of hyperphosphatemia, which will include a cost
effective, nontoxic, palatable phosphate binder that does
not induce a metabolic imbalance or detrimentally ac-
cumulate in tissues. Stanley Goldfarb of the American
Society of Nephrology suggested in March 2004, “While
there is some evidence implicating calcium-containing
phosphate binders in cardiac calcification and vascular
disease in chronic hemodialysis, the hypothesis [that] the
calcium-containing binders are the root cause of vascular
and cardiac calcification is largely unproven. As calcium
acetate is more cost-effective than sevelamer, and is ef-
fective in controlling serum phosphate, it is an accepted
first-line drug therapy.”
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